[Safety aspects of treatments with hrGH].
Recombinant human growth hormone (hrGH) has been used for treatment of growth hormone deficient children over 20 years and it can be considered to have an excellent safety profile. The main international surveys show few adverse drug reactions reported, specially in idiopathic growth hormone deficiency and in idiopathic short stature. With regard to cancer risk or tumor recurrence, it seems that there is no greater risk with hrGH treatment in comparison to general population. The idiopathic intracranial hypertension is a rare condition, but its incidence is higher in patients with chronic renal failure. The adverse events are rare in patients treated with hrGH, but these patients should be carefully monitored, specially those with pharmacologycal doses or with another clinical condition of greater risk.
Kochi
Cristiane
C
Unidade de Endocrinologia Pediátrica, Santa Casa de São Paulo, SP, Brazil. ckochi@uol.com.br
D006130:Growth Disorders / Q000188:drug therapy*; D019382:Human Growth Hormone / Q000009:adverse effects*; D006801:Humans; D007427:Intracranial Pressure / Q000187:drug effects; D007676:Kidney Failure, Chronic / Q000150:complications; D011994:Recombinant Proteins / Q000009:adverse effects
D011994:Recombinant Proteins; D019382:Human Growth Hormone